Citadel Advisors’s Fidelity Disruptive Medicine ETF FMED Stock Holding History

Citadel Advisors’s Portfolio FMED Stock Details FMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$282K	Buy	+9,896	New	+$251K	﹤0.01%	11249

Other funds holding FMED

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

OMC

Old Mission Capital Chicago, Illinois $6.31B AUM 20.77% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

CPBTD

Central Pacific Bank - Trust Division Honolulu, Hawaii $984M AUM 34.19% 1-Year Est. Return

GEA

Glen Eagle Advisors Kingston, New Jersey $793M AUM 21.06% 1-Year Est. Return

GJIA

Glass Jacobson Investment Advisors Owings Mills, Maryland $321M AUM 20.69% 1-Year Est. Return

Citadel Advisors's FMED Position: Q2 2026 in Review

Citadel Advisors opened a new position in Fidelity Disruptive Medicine ETF (FMED) in Q2 2026: 9,896 shares worth $282K. The stake represents ﹤0.01% of the portfolio and ranks #11249 among its holdings.

11 funds tracked by Wall St. Rank hold FMED as of Q2 2026.

Citadel Advisors held 9,896 shares of Fidelity Disruptive Medicine ETF worth $282K as of Q2 2026.
Fidelity Disruptive Medicine ETF was a new Citadel Advisors position in Q2 2026.
Fidelity Disruptive Medicine ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11249 holding.
11 funds tracked by Wall St. Rank held Fidelity Disruptive Medicine ETF as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.